1. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infectious diseases 2013; 13: 976-86.
2. Nabha L, Duong L, Timpone J. HIV associated neurocognitive disorders: perspectives on management strategies. Drugs 2013; 73(9): 893-905, June.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J. Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2008; 69(18): 1789-99.
4. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest, D.J. For the A5170 Study Team. Neurocognition effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74: 1260-1266.
5. Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. British HIV Association HIV Medicine 2009;10; 246-252
6. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J. Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2008; 69(18): 1789-99.
7. McArthur J, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Annals of Neurology 2010;67:699–714.
8. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J. Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2008; 69(18): 1789-99.
9. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E. 2005. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS Sep 2; 19(13):1367-74.
10. Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA. (2016). A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis. 2016 Sep 1; 63(5):687-693
11. Achappa B, Priyadarshni S, Madi D, Bhaskaran U, Ramapuram JT, Rao, S, Chowta M, Mahalingam S. Neurocognitive dysfunction among HIV positive patients using International HIV dementia scale. Asian Journal of Medical Sciences 2014; Oct-Nov Vol 5 Issue 4 61-64.
12. Atluri VSR, Kurapati KRV, Samikkannu T, Nair MPN. Biomarkers of HIV Associated Neurocognitive Disorders. JSM Biomarkers 2014; 1(1):1002.
13. Folstein MF, Folstein SE, McHugh PR.1975. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 Nov; 12(3):189-98.
14. Atluri VSR, Kurapati KRV, Samikkannu T, Nair MPN. Biomarkers of HIV Associated Neurocognitive Disorders. JSM Biomarkers 2014; 1(1):1002.
15. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre S L, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan T, Wong J, Grant I. CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75(23): 2087-96.
16. Nabha L, Duong L, Timpone J. HIV associated neurocognitive disorders: perspectives on management strategies. Drugs 2013; 73(9): 893-905, June.
17. del Palacio M, Alvarez S, Munoz-Fernandez, MA. HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol 2012; 22(1): 33-45, Jan.
18. Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: can serological studies establish a clear relationship? Neurological Science. 2013; 34(4):417-25. doi: 10.1007/s10072-012-1197-4, April.
19. Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS. 2004;18 (Suppl 1:S79 – 86).
20. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I. CHARTER Group. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011;10: 25(14): 10.1097/QAD.0b013e32834a40cd, Sept 10.
21. Fiala M, Eshleman A J, Cashman J, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. Journal of Neurovirology 2005; 11, 281–29110.1080/13550280590952835
22. Fiala M, Eshleman A J, Cashman J, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. Journal of Neurovirology 2005; 11, 281–29110.1080/13550280590952835
23. Schouten J, Wit FW, Stolte IG, et al. Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study. Oral abstract. AIDS 2012: XIX International AIDS Conference: Abstract THAB0205. Presented 2012, July 26.
24. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K, CASCADE Collaboration. ( 2008). Ann Neurol. Feb; 63(2):213-21.
25. McArthur J, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Annals of Neurology 2010;67:699–714.
26. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J. Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2008; 69(18): 1789-99.
27. Letendre SL, FitzSimons C, Ellis RJ, Clifford D, Collier AC, Gelman B, Marra C, Macarthur J, McCutchan JA, Morgello S, Simpson D, Vaida F, Heaton R, Grant I, and the CHARTER Group. Correlates of CSF Viral Loads in 1,221 volunteers of the CHARTER cohort. 17th Conference on Retroviruses and Opportunistic Infections, 2010.
28. Cystique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73(5), 342-8.
29. In a conversation with Dr. Bruce Brew, 2012.
30. Letendre SL, FitzSimons C, Ellis RJ, Clifford D, Collier AC, Gelman B, Marra C, Macarthur J, McCutchan JA, Morgello S, Simpson D, Vaida F, Heaton R, Grant I, and the CHARTER Group. Correlates of CSF Viral Loads in 1,221 volunteers of the CHARTER cohort. 17th Conference on Retroviruses and Opportunistic Infections, 2010. {ref} (Table 7). Use of this tool is controversial with studies yielding mixed results, some with greater benefit than others {ref} Eggers C, Arendt G, Hahn K,Husstedt IW, Maschke M, Neuen-Jacob E, Obermann M, Rosenkranz T, Schielke E, Straube E; German Association of Neuro-AIDS und Neuro-Infectiology (DGNANI). (2017).HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. Journal of Neurology, Aug;264(8):1715-1727. doi: 10.1007/s00415-017-8503-2. Epub 2017 May 31.
31. Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Gunthard HF, Swiss HIVCS (2013) Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of the Acquired Immune Deficiency Syndrome Human Retroviroogy,l 62:28–35; Cysique LA, Waters EK, Brew BJ (2011). Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurology, 11:148
32. Carroll, A & Brew, B. (2017). HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Research, 6: 312. Published online 2017 Mar 23. doi: 10.12688/f1000research.10651.1 .
33. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest, D.J. For the A5170 Study Team. Neurocognition effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74: 1260-1266.
34. Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. British HIV Association HIV Medicine 2009;10; 246-252
35. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest, D.J. For the A5170 Study Team. Neurocognition effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74: 1260-1266.
36. Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. British HIV Association HIV Medicine 2009;10; 246-252